Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

被引：0
|
作者：
Gaetano Chirico
Roberto Ravasio
Urbano Sbarigia
机构：
[1] Spedali Civili,Neonatologia e Terapia Intensiva Neonatale
[2] Wolters Kluwer Health/Adis International Ltd,Health Economics
[3] Market Access & Health Policies,undefined
来源：
Italian Journal of Pediatrics | / 35卷
关键词：
Preterm Infant; Respiratory Syncytial Virus; Incremental Cost; Incremental Cost Effectiveness Ratio; Respiratory Syncytial Virus Infection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age
    Keary, Ian P.
    Ravasio, Roberto
    Fullarton, John R.
    Manzoni, Paolo
    Lanari, Marcello
    Paes, Bosco A.
    Carbonell-Estrany, Xavier
    Baraldi, Eugenio
    Tarride, Jean-Eric
    Rodgers-Gray, Barry
    [J]. PLOS ONE, 2023, 18 (08):
  • [42] A cost-benefit analysis of RSV prophylaxis in high-risk infants
    Schrand, LM
    Elliott, JM
    Ross, MB
    Bell, EF
    Mutnick, AH
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (10) : 1186 - 1193
  • [43] Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis
    Checchia, Paul A.
    Nalysnyk, Luba
    Fernandes, Ancilla W.
    Mahadevia, Parthiv J.
    Xu, Yingxin
    Fahrbach, Kyle
    Welliver, Robert C., Sr.
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (05) : 580 - 588
  • [44] EFFICACY OF RIBAVIRIN FOR TREATING RESPIRATORY SYNCYTIAL VIRUS (RSV) PNEUMONIA IN HIGH-RISK INFANTS
    SPINELLI, M
    GERACICIARDULLO, K
    PALUMBO, PE
    LASKIN, O
    EDELSON, PJ
    [J]. PEDIATRIC RESEARCH, 1985, 19 (04) : A304 - A304
  • [45] The effect of Palivizumab in the incidence rate of hospitalisation for Respiratory Syncytial Virus infection in high-risk preterm infants in Doha, Qatar: three-year retrospective
    Elmasoudi, Ahmed
    Robson, Tracy
    Badran, Hoda
    Khalil, Ahmed
    [J]. PHARMACOTHERAPY, 2015, 35 (11): : E255 - E255
  • [46] Respiratory syncytial virus prophylaxis in a high-risk population in Argentina - A cost-effectiveness analysis
    Rodriguez, Susana P.
    Farina, Diana
    Bauer, Gabriela
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (07) : 660 - 661
  • [47] Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
    Elhalik, M.
    El-Atawi, K.
    Dash, S. K.
    Faquih, A.
    Satyan, A. D.
    Gourshettiwar, N.
    Khan, A.
    Varughese, S.
    Ramesh, A.
    Khamis, E.
    [J]. CANADIAN RESPIRATORY JOURNAL, 2019, 2019
  • [48] Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    Meissner, HC
    Welliver, RC
    Chartrand, SA
    Law, BJ
    Weisman, LE
    Dorkin, HL
    Rodriguez, WJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (03) : 223 - 231
  • [49] Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan
    Kusuda, Satoshi
    Takahashi, Naoto
    Saitoh, Takami
    Terai, Masaru
    Kaneda, Hisashi
    Kato, Yuichi
    Ohashi, Atsushi
    Watabe, Shinichi
    Joh-o, Kunitaka
    Hirai, Katsuki
    [J]. PEDIATRICS INTERNATIONAL, 2011, 53 (03) : 368 - 373
  • [50] Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey
    Oncel, Mehmet Yekta
    Mutlu, Banu
    Kavurt, Sumru
    Bas, Ahmet Yagmur
    Demirel, Nihal
    Akyol, Mesut
    Erdeve, Omer
    Dilmen, Ugur
    [J]. TURKISH JOURNAL OF PEDIATRICS, 2012, 54 (04) : 344 - 351
12345